Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B

Hepatology

Volumn 32, Issue 5, 2000, Pages 1078-1088

  Ahmed, Si Nafa Si ^b   Tavan, David ^b   Pichoud, Christian ^a   Berby, Françoise ^a   Stuyver, Lieven ^c   Johnson, Mark ^d   Merle, Philippe ^b   Abidi, Hassane ^e   Trépo, Christian ^a,b   Zoulim, Fabien ^a,b  

^a INSERM   (France)

^b HÔTEL DIEU   (France)

^c INNOGENETICS   (Belgium)

^d GLAXOSMITHKLINE   (United States)

^e CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; FAMCICLOVIR; LAMIVUDINE; VIDARABINE; VIRUS DNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FUNCTION; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS DETECTION; VIRUS HEPATITIS; VIRUS RESISTANCE;

EID: 0033761078     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.19619     Document Type: Article

References (48)

1. A preliminary trial of lamivudine for chronic hepatitis B infection
2. Lamivudine as initial treatment for chronic hepatitis B in the United States
3. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
4. A one year trial of lamivudine for chronic hepatitis B
5. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
6. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group
7. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
8. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: Hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss
9. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
10. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
11. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
12. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment
13. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B
14. Drug therapy for chronic hepatitis B: Antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy
15. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
16. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance
17. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus
18. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection
19. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors
20. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues
21. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy
22. Comparison of methods for detection of hepatitis B virus DNA
23. Clinical evaluation and applications of the amplicor HBV monitorTM test, a quantitative HBV DNA PCR assay
24. Evaluation of a new assay for HBV DNA quantitation in patients with chronic hepatitis B
25. Variable expression of pre-S1 antigen in serum during chronic hepatitis B virus infection: An accurate marker for the level of hepatitis B virus replication
26. A line probe assay for hepatitis B virus genotypes
27. Three cases of severe subfulminant hepatitis in heart-transplanted patients after nosocomial transmission of a mutant hepatitis B virus
28. Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B
29. Rapid detection of mutations in the promoter and the pre-core region of HBV genome: Correlation with viral persistence and disease activity
30. High-performance liquid chromatographic assay for 2'-deoxy-3'-thiacytidine in human serum
31. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine
32. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine
33. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBlg immunoglobulin after liver transplantation
34. Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo
35. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine
36. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance
37. Genotypic resistance to lamivudine in a prospective, placebo-controlled multicentre study in Asia of lamivudine therapy for chronic hepatitis B infection: Incidence, kinetics of emergence and correlation with disease parameters
38. Naturally occurring variants of hepatitis B virus
39. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro
40. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group
41. Clinical pharmacokinetics of lamivudine
42. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
43. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
44. Detection of hepatitis B virus DNA in liver and serum: A direct appraisal of the chronic carrier state
45. Lamivudine therapy of WHV-infected woodchucks
46. Effect of interferon alpha on hepatitis B virus replication and gene expression in transiently transfected human hepatoma cells
47. The hepatitis B virus and the host response
48. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro